# The Evaluation of Belimumab in Myasthenia Gravis (MG)

> **NCT01480596** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 40 (actual)

## Conditions studied

- Myasthaenia Gravis

## Interventions

- **BIOLOGICAL:** Belimumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01480596
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2015-08
- **Final completion:** 2015-10
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01480596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01480596, "The Evaluation of Belimumab in Myasthenia Gravis (MG)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01480596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*